OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Safety and tolerability of esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression
Roger S. McIntyre, István Bitter, Jozefien Buyze, et al.
European Neuropsychopharmacology (2024) Vol. 85, pp. 58-65
Open Access | Times Cited: 8
Roger S. McIntyre, István Bitter, Jozefien Buyze, et al.
European Neuropsychopharmacology (2024) Vol. 85, pp. 58-65
Open Access | Times Cited: 8
Showing 8 citing articles:
Improvements in functioning and workplace productivity with esketamine nasal spray versus quetiapine extended release in patients with treatment resistant depression: Findings from a 32-week randomised, open-label, rater-blinded phase IIIb study
Eduard Vieta, Nahida Ahmed, Celso Arango, et al.
European Neuropsychopharmacology (2025) Vol. 93, pp. 29-39
Open Access | Times Cited: 2
Eduard Vieta, Nahida Ahmed, Celso Arango, et al.
European Neuropsychopharmacology (2025) Vol. 93, pp. 29-39
Open Access | Times Cited: 2
Six Years After Approval of Esketamine Nasal Spray for Serious Depression: Clinical Conundrums and Unanswered Questions
Sanjay J. Mathew, Nicholas Murphy
American Journal of Psychiatry (2025) Vol. 182, Iss. 3, pp. 227-230
Closed Access | Times Cited: 1
Sanjay J. Mathew, Nicholas Murphy
American Journal of Psychiatry (2025) Vol. 182, Iss. 3, pp. 227-230
Closed Access | Times Cited: 1
Association between major cardiovascular events and esketamine: A disproportionality analysis in the WHO pharmacovigilance database
Tanguy Taillefer de Laportalière, Mark Horowitz, Thomas Soeiro, et al.
European Neuropsychopharmacology (2025) Vol. 96, pp. 12-14
Closed Access
Tanguy Taillefer de Laportalière, Mark Horowitz, Thomas Soeiro, et al.
European Neuropsychopharmacology (2025) Vol. 96, pp. 12-14
Closed Access
The effects of ketamine and esketamine on measures of quality of life in major and treatment-resistant depression: A systematic review
M Cheng, Christine E Dri, Hana Ballum, et al.
Journal of Affective Disorders (2025) Vol. 382, pp. 438-442
Closed Access
M Cheng, Christine E Dri, Hana Ballum, et al.
Journal of Affective Disorders (2025) Vol. 382, pp. 438-442
Closed Access
Treatment-resistant depression and intranasal esketamine: Spanish clinical consensus on practical aspects
Josep Antoni Ramos‐Quiroga, Fernando Mora, Silvia Arostegui, et al.
The European Journal of Psychiatry (2025) Vol. 39, Iss. 3, pp. 100313-100313
Open Access
Josep Antoni Ramos‐Quiroga, Fernando Mora, Silvia Arostegui, et al.
The European Journal of Psychiatry (2025) Vol. 39, Iss. 3, pp. 100313-100313
Open Access
Psychedelika und Dissoziativa in der Psychiatrie: Herausforderungen in der Behandlung
Johannes Jungwirth, Francesco Bavato, Boris B. Quednow
Der Nervenarzt (2024) Vol. 95, Iss. 9, pp. 803-810
Open Access | Times Cited: 1
Johannes Jungwirth, Francesco Bavato, Boris B. Quednow
Der Nervenarzt (2024) Vol. 95, Iss. 9, pp. 803-810
Open Access | Times Cited: 1
Psychiatric first-aid kit: A review of EMA's critical medicines list
Eduard Vieta, Lídia Ilzarbe
European Neuropsychopharmacology (2024) Vol. 89, pp. 26-27
Closed Access | Times Cited: 1
Eduard Vieta, Lídia Ilzarbe
European Neuropsychopharmacology (2024) Vol. 89, pp. 26-27
Closed Access | Times Cited: 1
Esketamine Nasal Spray: Rapid Relief for TRD and Suicide Prevention—Mechanisms and Pharmacodynamics
Hui Song, Yang Luo, Lingzhi Fang
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 2059-2071
Open Access | Times Cited: 1
Hui Song, Yang Luo, Lingzhi Fang
Neuropsychiatric Disease and Treatment (2024) Vol. Volume 20, pp. 2059-2071
Open Access | Times Cited: 1
